BridgeMD
A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma
EU CTIS ID: 2024-510913-13-00
What this study is testing
Phase 3 portion of the trial - To compare progression-free survival (PFS) of BMS-986213 to nivolumab monotherapy in participants with previously untreated, unresectable or metastatic melanoma. Phase 2 portion of the trial - To compare PFS of BMS-986213 to nivolumab monotherapy in participants with previously untreated, unresectable or metastatic melanoma.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
- Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma
- Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses
You likely can't join if
- Participants must not have active brain metastases or leptomeningeal metastases
- Participants must not have uveal melanoma
- Participants must not have an active, known, or suspected autoimmune disease
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- United States
- Argentina
- Colombia
- Israel
- Taiwan
- Canada
- United Kingdom
- Australia
- Chile
- Korea, Republic of
- Switzerland
- Japan
- Russian Federation
- Brazil
- New Zealand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; United States; Argentina; Colombia; Israel; Taiwan and 10 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.